<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810302</url>
  </required_header>
  <id_info>
    <org_study_id>034-2013</org_study_id>
    <nct_id>NCT01810302</nct_id>
  </id_info>
  <brief_title>Safety Study of Nicardipine to Treat Cerebral Vasospasm</brief_title>
  <official_title>Intraventricular Nicardipine for the Treatment of Cerebral Vasospasm: Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if intrathecal nicardipine is safe for the
      treatment of cerebral vasospasm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subarachnoid hemorrhage accounts for approximately 5% of all strokes and affects 30,000
      Americans per year. Poor outcome from aneurysmal subarachnoid hemorrhage (SAH) occurs in 50
      to 75% of patients, and this is attributed to secondary ischemia in approximately 30% of
      patients. This delayed cerebral ischemia has been attributed to the anatomic narrowing of
      arteries in the cerebral vasculature which occurs following SAH.

      Because of this relationship between cerebral vasospasm, cerebral ischemia, and poor outcome,
      there has been significant effort to establish treatments that decrease the incidence of
      vasospasm after SAH. Currently, medications and hemodynamic maneuvers are used as standard of
      care for the treatment of vasospasm and to improve outcome after SAH.

      The calcium channel blocker, nimodipine, is one of the few treatments for vasospasm that has
      been shown to be of proven benefit. Nicardipine is another calcium channel blocker that has
      been evaluated in several studies via an intravenous administration route. These studies did
      show significant improvements in symptomatic and angiographic vasospasm, although a benefit
      in outcome was not seen. However, the intravenous administration of nicardipine was
      associated with significant systemic side effects that may have affected outcome including
      hypotension, pulmonary edema, and azotemia.

      The administration of nicardipine via an intrathecal route avoids the systemic complications
      associated with intravenous dosing since the direct cerebrospinal fluid dosing is much lower.
      The result is that the systemic concentration will remain low avoiding systemic side effects,
      and central nervous system concentration will remain high. We propose that this difference
      may improve outcomes while minimizing complication related effects on patient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to secure drug.
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Bacterial Meningitis.</measure>
    <time_frame>Day 1 of study drug until post-hemorrhage day 10.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cerebral Vasospasm.</measure>
    <time_frame>Day 1 of study drug until post-hemorrhage day 10.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Nicardipine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preservative-free normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicardipine hydrochloride</intervention_name>
    <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
    <arm_group_label>Nicardipine hydrochloride</arm_group_label>
    <other_name>Nicardipine</other_name>
    <other_name>Cardene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative-free normal saline</intervention_name>
    <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
    <arm_group_label>Preservative-free normal saline</arm_group_label>
    <other_name>Normal saline</other_name>
    <other_name>Placebo</other_name>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age and older

          -  Subarachnoid hemorrhage documented on head CT

          -  Fisher Grade 3 or 4

          -  Hunt Hess Grade 1-5

          -  Cerebral aneurysm as definitive source of subarachnoid hemorrhage

          -  Cerebral aneurysm must be treated via open or endovascular techniques

          -  Presence of external ventricular drain

          -  Written informed consent obtained from subject or subject's legally authorized
             representative

        Exclusion Criteria:

          -  Absence or inability to have an external ventricular drain (coagulopathy)

          -  Non-aneurysmal subarachnoid hemorrhage (perimesencephalic)

          -  Untreated cerebral aneurysm

          -  Inability to be randomized prior to post-hemorrhage day 4

          -  Elevated intra-cranial pressures that would preclude external ventricular drain
             clamping for 30-60 minutes

          -  Inability to administer study medication (severe intra-ventricular hemorrhage,
             occluded external ventricular drain)

          -  Inability to obtain angiography (coagulopathy, renal failure)

          -  Pregnant

          -  Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spiros L. Blackburn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2013</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <results_first_submitted>August 18, 2014</results_first_submitted>
  <results_first_submitted_qc>August 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasospasm</keyword>
  <keyword>Subarachnoid hemorrhage</keyword>
  <keyword>Aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>Nicardipine</keyword>
  <keyword>Intrathecal</keyword>
  <keyword>SAH</keyword>
  <keyword>aSAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasospasm, Intracranial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicardipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicardipine Hydrochloride</title>
          <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Nicardipine hydrochloride: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
        </group>
        <group group_id="P2">
          <title>Preservative-free Normal Saline</title>
          <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Preservative-free normal saline: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicardipine Hydrochloride</title>
          <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Nicardipine hydrochloride: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
        </group>
        <group group_id="B2">
          <title>Preservative-free Normal Saline</title>
          <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Preservative-free normal saline: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Bacterial Meningitis.</title>
        <time_frame>Day 1 of study drug until post-hemorrhage day 10.</time_frame>
        <population>Number of participants were not sufficient to perform data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicardipine Hydrochloride</title>
            <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Nicardipine hydrochloride: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
          </group>
          <group group_id="O2">
            <title>Preservative-free Normal Saline</title>
            <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Preservative-free normal saline: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bacterial Meningitis.</title>
          <population>Number of participants were not sufficient to perform data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cerebral Vasospasm.</title>
        <time_frame>Day 1 of study drug until post-hemorrhage day 10.</time_frame>
        <population>Number of participants were not sufficient to perform data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicardipine Hydrochloride</title>
            <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Nicardipine hydrochloride: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
          </group>
          <group group_id="O2">
            <title>Preservative-free Normal Saline</title>
            <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Preservative-free normal saline: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cerebral Vasospasm.</title>
          <population>Number of participants were not sufficient to perform data analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event monitoring began at the initiation of study procedures and continued until post-hemorrhage day 17.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nicardipine Hydrochloride</title>
          <description>Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
Nicardipine hydrochloride: Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.</description>
        </group>
        <group group_id="E2">
          <title>Preservative-free Normal Saline</title>
          <description>Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
Preservative-free normal saline: Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastointestinal Bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gastic Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Cerebrospinal Fluid Leakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Thromboembolic Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This single center study was terminated early due to inability to maintain an adequate drug supply; therefore, statistical analysis of the 2 participants was not done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Spiros Blackburn</name_or_title>
      <organization>University of Florida</organization>
      <phone>(352) 273-9000</phone>
      <email>spiros.blackburn@neurosurgery.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

